These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35659487)

  • 1. Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults.
    Loong D; Pham B; Amiri M; Saunders H; Mishra S; Radhakrishnan A; Rodrigues M; Yeung MW; Muller MP; Straus SE; Tricco AC; Isaranuwatchai W
    Value Health; 2022 Aug; 25(8):1439-1458. PubMed ID: 35659487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
    Jiang M; Li P; Wang W; Zhao M; Atif N; Zhu S; Fang Y
    Vaccine; 2020 Jan; 38(5):1057-1064. PubMed ID: 31787414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
    Gärtner BC; Weinke T; Wahle K; Kwetkat A; Beier D; Schmidt KJ; Schwarz TF
    Vaccine; 2022 May; 40(22):2999-3008. PubMed ID: 35459556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
    Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
    BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
    Yan H; Yang J; Chen ZY; Gong H; Zhong GJ; Yu HJ
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2405-2412. PubMed ID: 34404135
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.
    You JH; Ming WK; Chan PK
    BMC Infect Dis; 2014 Nov; 14():618. PubMed ID: 25420713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly.
    Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
    Vaccine; 2019 Apr; 37(15):2051-2056. PubMed ID: 30871927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
    Mennini FS; Bini C; Marcellusi A; Rinaldi A; Franco E
    Hum Vaccin Immunother; 2018; 14(8):1867-1873. PubMed ID: 29708843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.
    Capri S; Barbieri M; de Waure C; Boccalini S; Panatto D
    Hum Vaccin Immunother; 2018 Jun; 14(6):1331-1341. PubMed ID: 29425079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
    Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population.
    Rumi F; Basile M; Cicchetti A; Alvarez FP; Azzi MV; Muzii B
    Front Public Health; 2023; 11():1200116. PubMed ID: 38026422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability.
    Hendriks J; Hutubessy RCW; Grohmann G; Torelli G; Friede M; Kieny MP
    Vaccine; 2018 Jun; 36(28):3993-3997. PubMed ID: 29866617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.
    Bianculli PM; Bellier L; Mangado IO; Pérez CG; Mieres G; Lazarov L; Petitjean A; Dibarboure H; Lopez JG
    Hum Vaccin Immunother; 2022 Nov; 18(5):2050653. PubMed ID: 35344679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom.
    Kohli MA; Maschio M; Mould-Quevedo JF; Drummond M; Weinstein MC
    Hum Vaccin Immunother; 2021 Nov; 17(11):4603-4610. PubMed ID: 34550848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis.
    Coleman BL; Sanderson R; Haag MDM; McGovern I
    Influenza Other Respir Viruses; 2021 Nov; 15(6):813-823. PubMed ID: 34081398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
    Mullikin M; Tan L; Jansen JP; Van Ranst M; Farkas N; Petri E
    Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season.
    Pelton SI; Divino V; Postma MJ; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G
    Vaccine; 2021 Apr; 39(17):2396-2407. PubMed ID: 33810903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.
    Beran J; Peeters M; Dewé W; Raupachová J; Hobzová L; Devaster JM
    BMC Infect Dis; 2013 May; 13():224. PubMed ID: 23688546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Utility of Switching From Trivalent to Quadrivalent Influenza Vaccine in Turkey.
    Amiche A; Tanriover MD; Bellier L; Ugur B; Akin L
    Value Health Reg Issues; 2021 Sep; 25():15-22. PubMed ID: 33485248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.